Stockreport

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

LENZ Therapeutics, Inc.  (LENZ) 
PDF Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 C [Read more]